Autopsy report · NCT02944721

Genetic, Neurophysiological and Psychological Predictive Factors of Chronic Neuropathic Pain After Surgery for Breast Cancer

“change of sponsor”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Hopital Foch

Sponsor type

University, hospital or other

Conditions

Breast Cancer

Interventions

Genetical analyses; Chronic pain identification questionnaires; Neurophysiological and psychophysical evaluations; Quality of life questionnaires

Participants

0

Sites

2

Countries

France

Trials that died the same way

• VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure
  “Change in Sponsor” (98% match in meaning)
• Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy
  “Sponsor change” (97% match in meaning)
• POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
  “Change in Sponsor strategy” (86% match in meaning)
• Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients
  “sponsor strategy change” (84% match in meaning)
• Safety and Efficacy of Gaseous Nitric Oxide on Venous Stasis Leg Ulcers
  “Strategic direction of the sponsor changed” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.